[The peptide analogue of neurotensin with antipsychotic and pro-cognitive effects: results of the pilot clinical trial].
Observational study · 2020
- What was studied
- 25 patients with schizotypal disorder
- Main finding
- A 25-person Dilept pilot reported psychiatric and cognitive improvement, most evident at 200 mg/day; it did not provide numerical symptom-score changes in its abstract.
Reported findings and study design
A 25-person Dilept pilot reported psychiatric and cognitive improvement, most evident at 200 mg/day; it did not provide numerical symptom-score changes in its abstract.
25 patients with schizotypal disorder; 14-day monotherapy phase with limited rescue phenazepam, followed by combination treatment if needed.
Dose, route and schedule
Dilept: 60, 120 or 200 mg/day for 14 days as monotherapy. Single 2 mg doses of phenazepam were permitted as rescue treatment; subsequent combination treatment must be distinguished from the monotherapy phase.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Psychiatric and cognitive measures | Reported favorable changes; no PANSS, CGI or WAIS-R deltas supplied | |
| Participants | 25; mean age 33.4 ± 10.0 years | |
| Studied doses | 60, 120 and 200 mg/day; strongest reported action at 200 mg/day |
Small uncontrolled pilot with rescue and subsequent combination therapy; claims about superiority to other antipsychotics are not established by this design.
Source for these results ↗ · Reviewed 2026-11-01
Study limitations and source details
Study limitations
- Small pilot with permitted or add-on phenazepam. The same 25 patients are described in the 2017 cognitive report. The 2021 active comparison may reuse the 15-person high-dose arm.
Related publications may describe some of the same participants or experiments.
Source details
Original full paper and 2017 dose-finding publication, with cohort comparison.
Full paper reviewed
Sources checked
Citation
Neznamov GG, Bogdanova IO, Sunyakov TS, Dorofeeva OA, Kovalenok TV, Chepeluk AA. [The peptide analogue of neurotensin with antipsychotic and pro-cognitive effects: results of the pilot clinical trial]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Study source ↗ · DOI 10.17116/jnevro202012002122 · Bibliography entry · Link to this summary